Phosphodiesterase (PDE)

Phosphodiesterase (PDE) Related Products (477):

By Effects:	Substrate (1) Controls (7) Inhibitors (418) Agonists (2) Activators (3) Modulators (2)

Cat. No.	Product Name	Effect	Purity

HY-153192

Nerandomilast	Inhibitor	99.93%
Nerandomilast (BI 1015550) is an orally active inhibitor of PDE4B with an IC₅₀ value of 7.2 nM. Nerandomilast has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD).

HY-B0312

Dipyridamole	Inhibitor	99.93%
Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis.

HY-100912

W-7 hydrochloride	Inhibitor	99.96%
W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca²⁺-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC₅₀ values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias.

HY-17464

Cilostazol	Inhibitor	99.83%
Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM.

HY-B0715

Pentoxifylline	Inhibitor	99.92%
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation.

HY-176708

ISM5939	Inhibitor
ISM5939 is an orally active and selective ENPP1 inhibitor with an IC₅₀ of 0.63 nM for 2,3-cGAMP degradation and 9.28 nM for ATP hydrolysis. ISM5939 has antitumor activity.

HY-152106B

(±)-BAY-7081	Inhibitor	99.06%
(±)-BAY-7081 is a racemate of BAY-7081 (HY-152106). BAY-7081 is a potent, selective, orally active and soluble cyanopyridone-based PDE9A inhibitor with an IC₅₀ of 15 nM.

HY-141831

STF-1084	Inhibitor	99.40%
STF-1084 is a specific, cell-impermeable, competitive inhibitor of ENPP1 (K_i = 33 nM). STF-1084 increases extracellular cGAMP concentrations by preventing its degradation by ENPP1, thereby enhancing immune infiltration. STF-1084 acts synergistically with ionizing radiation (IR) and cGAMP to delay tumor progression. STF-1084 can be used to study cancers with low immunogenicity.

HY-B0523A

Anagrelide hydrochloride	Inhibitor	99.39%
Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action.

HY-129490

Enpp-1-IN-1	Inhibitor	99.19%
Enpp-1-IN-1 is an effective selective enpp-1 (nucleotide pyrophosphatase-phosphodiesterase 1) inhibitor.

HY-14286

Levosimendan	Inhibitor	99.82%
Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.

HY-113556

Sappanone A	Inhibitor	99.87%
Sappanone A is an orally active homoisoflavone found in sappan L. Sappanone A is a PDE4 and NF-κB inhibitor with anti-inflammatory and antioxidant effect. Sappanone A induces HO-1 expression through activation of Nrf2 pathway. Sappanone A also inhibits RANKL-induced osteoclastogenesis. Sappanone A has great potential in the research of inflammation-related and cardiovascular .

HY-15426

PF-04957325	Inhibitor	99.55%
PF-04957325 is a highly potent and selective PDE8 inhibitor, with IC₅₀s of 0.7 nM and 0.3 nM for PDE8A and PDE8B, respectively.

HY-B0763

Ibudilast	Inhibitor	99.87%
Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia.

HY-103192

MDL12330A	Inhibitor	99.82%
MDL12330A (RMI12330A) is an adenyl cyclase inhibitor. MDL12330A inhibits the vasopressin action on the short-circuit current (SCC). MDL12330A is also an inhibitor of cAMP phosphodiesterase.

HY-111673

8-CPT-Cyclic AMP sodium	Inhibitor	99.92%
8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA) with an IC₅₀ of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC₅₀Epac and is a potent Epac activator.

HY-B0140

Aminophylline	Inhibitor	99.68%
Aminophylline is a competitive and non-selective phosphodiesterase (PDE) inhibitor. Aminophylline is a competitive adenosine receptor antagonist. Aminophylline has apulmonary vasodilator action as well as a bronchodilator action and has the potential for asthma research.

HY-N5012

Eurycomanone	Inhibitor	99.85%
Eurycomanone could increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis.

HY-B0128

Diphylline	Inhibitor	99.22%
Diphylline (Diprophylline) is a potent A1/A2 adenosine receptor antagonist and cyclic nucleotide phosphodiesterase inhibitor. Diphylline, a xanthine derivative, is a bronchodilator and vasodilator agent and has the potential for chronic bronchitis and emphysema.

HY-N0579

Fraxin	Inhibitor	99.88%
Fraxin isolated from Cortex Fraxini, is a glucoside of fraxetin and reported to exert potent anti-oxidative stress action, anti-inflammatory and antimetastatic properties. Fraxin shows its antioxidative effect through inhibition of cyclo AMP phosphodiesterase enzyme.

Name
Email *

	Sorry, but the email address you supplied was invalid.